Everett Harris & Co. CA reduced its stake in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,458,381 shares of the healthcare product maker’s stock after selling 8,766 shares during the period. Abbott Laboratories accounts for about 2.2% of Everett Harris & Co. CA’s investment portfolio, making the stock its 9th largest position. Everett Harris & Co. CA’s holdings in Abbott Laboratories were worth $182,721,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also modified their holdings of the stock. Cerity Partners LLC lifted its holdings in shares of Abbott Laboratories by 3.2% during the 4th quarter. Cerity Partners LLC now owns 1,579,648 shares of the healthcare product maker’s stock worth $197,911,000 after acquiring an additional 49,320 shares during the period. LPL Financial LLC lifted its holdings in shares of Abbott Laboratories by 9.8% during the 4th quarter. LPL Financial LLC now owns 2,168,901 shares of the healthcare product maker’s stock worth $271,742,000 after acquiring an additional 193,240 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Abbott Laboratories by 8.3% during the 4th quarter. Franklin Resources Inc. now owns 11,155,088 shares of the healthcare product maker’s stock worth $1,397,620,000 after acquiring an additional 851,767 shares during the period. Erste Asset Management GmbH lifted its holdings in shares of Abbott Laboratories by 32.8% during the 4th quarter. Erste Asset Management GmbH now owns 1,510,824 shares of the healthcare product maker’s stock worth $188,898,000 after acquiring an additional 373,560 shares during the period. Finally, CenterBook Partners LP purchased a new position in shares of Abbott Laboratories during the 4th quarter worth about $1,394,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity at Abbott Laboratories
In other news, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction on Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 0.46% of the stock is owned by company insiders.
Abbott Laboratories Trading Down 0.7%
Abbott Laboratories (NYSE:ABT – Get Free Report) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion during the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter last year, the company earned $1.09 earnings per share. Abbott Laboratories’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.
Analysts Set New Price Targets
Several research analysts have recently weighed in on ABT shares. Royal Bank Of Canada cut their price objective on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Weiss Ratings lowered shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, April 24th. Wells Fargo & Company cut their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Mizuho cut their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Finally, Argus cut their price target on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $119.09.
Get Our Latest Stock Analysis on Abbott Laboratories
Abbott Laboratories Company Profile
Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.
In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.
Featured Stories
- Five stocks we like better than Abbott Laboratories
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
